New strategies in the development of thrombolytic agents.
Lijnen
H R
HR
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
Collen
D
D
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D003328:Coronary Thrombosis / Q000188:drug therapy; D004285:Dogs; D015195:Drug Design; D005338:Fibrin Fibrinogen Degradation Products / Q000276:immunology; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007601:Jugular Veins; D010960:Plasminogen Activators / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D010980:Platelet Membrane Glycoproteins / Q000276:immunology; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D010980:Platelet Membrane Glycoproteins; D011994:Recombinant Proteins; C036309:fibrin fragment D; D010960:Plasminogen Activators